Perceptions and intentions regarding IQOS among current US adults who use cigarettes and/or electronic nicotine delivery systems
- PMID: 39740998
- PMCID: PMC12206933
- DOI: 10.1136/tc-2024-058854
Perceptions and intentions regarding IQOS among current US adults who use cigarettes and/or electronic nicotine delivery systems
Abstract
Introduction: IQOS was sold in the US in 2019-2021 and will likely return in 2024. It is important to anticipate IQOS' market penetration; thus, this study examined US adults' prior awareness and perceptions, intentions to try and reactions to an IQOS reduced-risk exposure statement.
Methods: 61 adults from three US cities were recruited to represent four tobacco use subgroups: current cigarette and never electronic nicotine delivery systems (ENDS) use; current cigarette and discontinued ENDS use; current cigarette and ENDS use; and former cigarette use and switched to ENDS. Participants were shown IQOS marketing material and probed about IQOS awareness, knowledge, perceptions, use intentions and reactions to a reduced exposure statement. Analysis used a hybrid inductive/deductive qualitative approach.
Results: Participants reported low awareness and knowledge of IQOS and uncertainty about its functionality and health effects. Other impressions varied by subgroup. People who currently smoked but never tried ENDS reacted mostly negatively to IQOS; people who had switched to ENDS were disinterested in returning to 'real tobacco' use; people who currently used cigarettes and ENDS were curious but had mixed feelings; and people who had rejected ENDS exhibited the greatest interest but were concerned about perceived cost. Reactions to the reduced exposure statement were mixed; some groups viewed it as a meaningful endorsement of harm reduction benefits while others were sceptical.
Conclusions: Across tobacco use groups, there was varied interest and inclination to try IQOS and thus varied potential use as a complete substitute for cigarettes.
Keywords: Electronic nicotine delivery devices; Harm Reduction; Non-cigarette tobacco products.
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: DLA has received funds for work done for the WHO Tobacco Free Initiative, as a Special Government Employee of the US Food and Drug Administration, as a consultant for Pfizer, as an employee of Cherokee National Operational Systems and as an independent contractor for McKing Consulting. TFP has provided unpaid expert testimony in lawsuits involving electronic cigarettes. ATE has supported research efforts for the FDA’s Center for Tobacco Products and the CDC’s Office of Smoking and Health. AG has supported qualitative research efforts for the US Food and Drug Administration. Other authors have no competing or conflicting interests to declare.
Similar articles
-
Interventions to reduce harm from continued tobacco use.Cochrane Database Syst Rev. 2016 Oct 13;10(10):CD005231. doi: 10.1002/14651858.CD005231.pub3. Cochrane Database Syst Rev. 2016. PMID: 27734465 Free PMC article.
-
Young Adults' Attention to Reduced Exposure Claims in IQOS Advertising and Associations With Product Perceptions and Use Intentions.Nicotine Tob Res. 2025 Jan 22;27(2):351-359. doi: 10.1093/ntr/ntae195. Nicotine Tob Res. 2025. PMID: 39109909 Free PMC article.
-
Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis.Health Technol Assess. 2021 Oct;25(59):1-224. doi: 10.3310/hta25590. Health Technol Assess. 2021. PMID: 34668482
-
Co-occurring Change in Electronic Nicotine Delivery System (ENDS) and Cigarette Harm Perceptions and Use in Young Adults.Nicotine Tob Res. 2025 Jun 23;27(7):1192-1199. doi: 10.1093/ntr/ntaf014. Nicotine Tob Res. 2025. PMID: 39820354
-
Heated tobacco products for smoking cessation and reducing smoking prevalence.Cochrane Database Syst Rev. 2022 Jan 6;1(1):CD013790. doi: 10.1002/14651858.CD013790.pub2. Cochrane Database Syst Rev. 2022. PMID: 34988969 Free PMC article.
References
-
- Food and Drug Administration C for T. Modified Risk Granted Orders. FDA. 2023. https://www.fda.gov/tobacco-products/advertising-and-promotion/modified-... (accessed 22 April 2024)
-
- U.S. International Trade Commission. Certain Tobacco Heating Articles and Components Thereof; Commission’s Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order and Cease and Desist Orders; Termination of the Investigation. 2021.
-
- Philip Morris International. Philip Morris International Submits Applications to Commercialize IQOS ILUMA Tobacco Heating System to U.S. Food and Drug Administration. https://www.pmi.com/media-center/press-releases/press-details (accessed 23 April 2024)
Grants and funding
LinkOut - more resources
Full Text Sources